Evidence map›Paper›PMID 40636670›Full record

ArticleFrontiers in cell and developmental biology2025

Correction: ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer.

Jinpeng Cen, Jiading Guo, Xianzi Zeng, Xianlu Song, Shengdong Ge, Mingkun Chen, Qianyi Li, Yuzhong Yu, Daojun Lv, Shanchao Zhao

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Jinpeng Cen *Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Jiading Guo *Department of Urology, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Xianzi Zeng *Department of Urology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Xianlu Song *Department of Radiotherapy, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Shengdong GeDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Mingkun ChenDepartment of Urology, The Fourth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Qianyi LiFirst Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, China.
Yuzhong YuDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Daojun LvDepartment of Urology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Shanchao ZhaoDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fcell.2025.1598400.].

Indexed as

androgen receptorCRPCELOVL2enzalutamide resistanceprostate cancer

Identifiers

PMID40636670
PMCPMC12238949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.